MT-RNR2 and neurodegenerative disease: Future studies with higher experimental models are necessary to validate its efficacy, assess long-term safety, and elucidate the underlying mechanisms before considering SHLP-6 as a potential therapeutic candidate for neurodegenerative diseases.